




RealRate

PHARMACEUTICAL 2021

XOMA Royalty Corp
Rank 117 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 46% points. The greatest weakness of XOMA Royalty Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 76% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	88,065
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,302
Liabilities, Non-Current	13,043
Other Assets	37,199
Other Compr. Net Income	0
Other Expenses	343
Other Liabilities	13,516
Other Net Income	1,225
Other Revenues	29,385
Property and Equipment	21
Research and Development	170
Selling, General and Administrative Expense	16,799

Output Variable	Value in 1000 USD
Assets	125,285
Liabilities	38,861
Expenses	17,312
Revenues	29,385
Stockholders Equity	86,424
Net Income	13,298
Comprehensive Net Income	13,298
BaseVar	106,034
ECR before LimitedLiability	246%
Economic Capital Ratio	333%